Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Max Bayer

Pharma Reporter

A proposal by HHS Secretary Robert F. Kennedy Jr. to change the approval standard of new vaccines shouldn’t affect BioNTech’s Covid-19 franchise, the company told …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Max Bayer

Pharma Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers to lay off over 500 workers in New Jersey

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Recursion cuts nearly half of its pipeline, including its most advanced program

PTC's Huntington’s study succeeds, but accelerated approval uncertain

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

Pharma Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact